Interestingly, the SSTR2-negative lesions could not be assigned to another molecular SCLC subtype via immunohistochemistry, in line with a recent study with no evidence for transcriptional subtype conversion on therapy (19). The gene discussed is SSTR2; the disease is small cell lung carcinoma.